Countries Consider Pandemic Pooling of Rights And Compulsory Licensing

Transparency of R&D Costs Also Requested

Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.

Coronavirus
Countries Consider How To Make COVID-19 Technologies Accessible

In an important move in the fight against the pandemic, Costa Rica has requested that the World Health Organization head an initiative to pool intellectual property rights relating to coronavirus technologies. Meanwhile Chile and Ecuador have paved the way for compulsory licenses, and the demand for more transparency on the costs of R&D and public financing is growing.

Costa Rica’s president, Carlos Alarado Quesada, and health minister Daniel Salas Peraza have written to the World Health Organization asking...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Latin America

Brazil Could Look To Germany, UK And Australia For ATMP Drug Pricing Rules

 

There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.

Argentina Speeds Up Market Access Process

 

Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.

Brazil’s Drug Pricing Shake Up Calls For More Robust Evidence From Companies

 

Brazil’s drug pricing authorities are planning to introduce, among other things, a new drug category for biosimilars to ensure the pricing procedures for such medicines are reflected in the official pricing framework.

Brazil To Upgrade Pricing Framework To Keep Up With Market Developments

 

Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.

More from Geography

Lerodalcibep And First Generic Palbociclib Among 10 New EMA Filings

 

Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization.

Welireg Among Japan Recommendations; Economic Policy Raises Hopes Of Higher Prices

 
• By 

Country recommends eights new drugs for approval, including six for rare diseases, and also announces macroeconomic policy the pharma industry says would enable some reimbursement prices to be raised.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.